McKesson is projected to report consolidated revenue of approximately $110.11 billion and adjusted EPS of $10.69 for the quarter ending September 30, 2026. The stock is currently trading at $1,002.71, slightly above the average analyst price target of $997.12.
Investors are laser-focused on the sustained demand for GLP-1 weight-loss medications and the growth of the high-margin Oncology and Multispecialty segment. Supporting this outlook is a strong fiscal Q1 performance where GLP-1 distribution revenue reached $15 billion, prompting management to raise its full-year earnings guidance. Additionally, the recent $2.25 billion acquisition of Precision Medicine Group underscores McKesson's strategic pivot toward higher-margin biopharma and specialty healthcare services.